STAT+: FDA approves a gene therapy for the inherited bleeding disorder hemophilia B

The Food and Drug Administration on Tuesday approved the first gene therapy to treat people with hemophilia B, an inherited bleeding disorder.

The one-time treatment, called Hemgenix, was developed by the Dutch biotech company UniQure and will be marketed by CSL Behring, an Australian pharmaceutical company.

Continue to STAT+ to read the full story…